Type(s) of biological therapy-Rituximab - Page 2 of 3 Posts on Medivizor
Navigation Menu

Type(s) of biological therapy-Rituximab Posts on Medivizor

Predicting outcomes for patients with DLBCL using the albumin to globulin ratio

Posted by on Aug 10, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the significance of the albumin to globulin ratio in pretreated patients with diffuse large B-cell lymphoma. The study concluded that this ratio was useful for predicting treatment outcomes in these patients. Some background R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) is the most...

Read More

Is pirarubicin safer and more effective than doxorubicin in R-CHOP for diffuse large B-cell lymphoma?

Posted by on Jul 15, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study compared the safety and effectiveness of two first-line chemotherapy regimens for diffuse large B-cell lymphoma. This study concluded that the R-THP-COP regimen was as effective as conventional R-CHOP for diffuse large B-cell lymphoma. Some background R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine,...

Read More

Chemotherapy after radiotherapy for early-stage follicular lymphoma

Posted by on Jul 14, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the safety and effectiveness of systemic chemotherapy after radiotherapy for early-stage follicular lymphoma. This study concluded that this combined treatment is more effective than radiotherapy alone for early-stage follicular lymphoma. Some background Radiotherapy can help control local disease in more than 90%...

Read More

Does 8 cycles of R-CHOP lead to better survival than 6 cycles for diffuse large B-cell lymphoma?

Posted by on Jun 21, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study examined whether 6 or 8 cycles of R-CHOP-21 (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy led to better survival outcomes in patients with newly diagnosed diffuse large B-cell lymphoma. This study concluded that outcomes following 6 or 8 cycles of R-CHOP-21 are similar for these patients. Some...

Read More

MOR208: a new antibody therapy for relapsed or refractory non-Hodgkin’s lymphoma

Posted by on Jun 9, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the safety and effectiveness of MOR208 in patients with relapsed or refractory (does not respond to treatment) non-Hodgkin’s lymphoma. This study concluded that MOR208 monotherapy was safe and showed promising results in these patients. Some background Chemoimmunotherapy is the current standard first-line...

Read More

Reviewing radiation therapy options for patients with relapsed or persistent DLBCL

Posted by on May 11, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study reviewed several studies involving patients with relapsed or refractory (does not respond to treatment) diffuse large B-cell lymphoma (DLBCL) who received radiation therapy (RT). The authors concluded that RT can improve outcomes and disease control for patients with localized disease. Some background Diffuse large B-cell...

Read More

Rituximab treatment for elderly patients with aggressive B-cell lymphomas

Posted by on Mar 10, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study looked at the impact of rituximab treatment and gene mutations on the outcomes for elderly patients who did not respond to first line chemotherpy. The study concluded that patients who experienced treatment failure after first line rituximab and chemotherapy had poor outcomes, but rituximab improved patient outcomes when...

Read More

Which chemotherapies increase the risk of developing pneumonitis in non-Hodgkin lymphoma?

Posted by on Mar 7, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study looks at how often patients being treated for non-Hodgkin lymphoma develop pneumonitis, a swelling of the lungs. The study concluded that patients being treated with R-CDOP chemotherapy are at the highest risk of developing pneumonitis.  Some background Pneumonitis is a dangerous and potentially deadly swelling of the...

Read More

Does PET/CT scanning during chemotherapy improve IPI-based outcome predictions for DLBCL patients?

Posted by on Feb 28, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated whether interim FDG PET/CT scanning during chemotherapy helps predict risk for new DLBCL (diffuse large B-cell lymphoma) patients. This study concluded that this scanning improves the risk classifications used to predict outcomes for DLBCL patients. Some background Diffuse large B-cell lymphoma (DLBCL) is the most...

Read More

Chemotherapy followed by radio-immunotherapy to treat patients with mantle cell lymphoma

Posted by on Feb 16, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study looked at the effectiveness of chemotherapy followed by a single dose of radio-immunotherapy for treating patients with mantle cell lymphoma. The study concluded that radio-immunotherapy after standard chemotherapy is safe and effective to treat patients with mantle cell lymphoma. Some background Mantle cell lymphoma (MCL)...

Read More